72 related articles for article (PubMed ID: 9066629)
21. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
22. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
[TBL] [Abstract][Full Text] [Related]
23. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
24. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
[TBL] [Abstract][Full Text] [Related]
25. Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
Jin S; Wang Y; Zhang Y; Zhang HZ; Wang SJ; Tang JQ; Chen HJ; Ge HL
Cancer Sci; 2008 Aug; 99(8):1670-8. PubMed ID: 18754882
[TBL] [Abstract][Full Text] [Related]
26. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.
Zaks TZ; Rosenberg SA
Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997
[TBL] [Abstract][Full Text] [Related]
27. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
Tsuda N; Chang DZ; Mine T; Efferson C; GarcĂa-Sastre A; Wang X; Ferrone S; Ioannides CG
Cancer Res; 2007 Sep; 67(17):8378-87. PubMed ID: 17804754
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
29. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma.
Lockhart DC; Chan AK; Mak S; Joo HG; Daust HA; Carritte A; Douville CC; Goedegebuure PS; Eberlein TJ
Surgery; 2001 Jun; 129(6):749-56. PubMed ID: 11391375
[TBL] [Abstract][Full Text] [Related]
30. Identification of T helper epitopes from prostatic acid phosphatase.
McNeel DG; Nguyen LD; Disis ML
Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
[TBL] [Abstract][Full Text] [Related]
31. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
32. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
33. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.
Ko BK; Efferson CL; Kawano K; Kuerer HM; Sahin A; Murray JL; Ioannides CG
Int J Oncol; 2004 Jun; 24(6):1413-8. PubMed ID: 15138582
[TBL] [Abstract][Full Text] [Related]
34. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
35. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen.
Hess AD; Thoburn CJ; Miura Y; Bright EC
Clin Immunol; 2005 Mar; 114(3):307-19. PubMed ID: 15721842
[TBL] [Abstract][Full Text] [Related]
36. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody.
Chatterjee SK; Tripathi PK; Chakraborty M; Yannelli J; Wang H; Foon KA; Maier CC; Blalock JE; Bhattacharya-Chatterjee M
Cancer Res; 1998 Mar; 58(6):1217-24. PubMed ID: 9515808
[TBL] [Abstract][Full Text] [Related]
37. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
38. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
39. Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates.
Ioannides CG; Platsoucas CD; Freedman RS
In Vivo; 1990; 4(1):17-24. PubMed ID: 2103838
[TBL] [Abstract][Full Text] [Related]
40. Sequence motifs of human her-2 protooncogene important for Peptide binding to hla-A2.
Fisk B; Chesak B; Ioannides M; Wharton J; Ioannides C
Int J Oncol; 1994 Jul; 5(1):51-63. PubMed ID: 21559557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]